Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma on the basis of recurrence-free and overall survival rates that were higher than those with placebo in a phase 3 trial. We wanted to determine the efficacy of nivolumab versus ipilimumab for adjuvant therapy in patients with resected advanced melanoma. METHODS: In this randomized, double-blind, phase 3 trial, we randomly assigned 906 patients (≥15 years of age) who were undergoing complete resection of stage IIIB, IIIC, or IV melanoma to receive an intravenous infusion of either nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks (453 patients) or ipilimumab at a dose of 10 mg per kilogram every 3 weeks for four doses and then every 12 weeks (453 patients). The patients were treated for a period of up to 1 year or until disease recurrence, a report of unacceptable toxic effects, or withdrawal of consent. The primary end point was recurrence-free survival in the intention-to-treat population. RESULTS: At a minimum follow-up of 18 months, the 12-month rate of recurrence-free survival was 70.5% (95% confidence interval [CI], 66.1 to 74.5) in the nivolumab group and 60.8% (95% CI, 56.0 to 65.2) in the ipilimumab group (hazard ratio for disease recurrence or death, 0.65; 97.56% CI, 0.51 to 0.83; P<0.001). Treatment-related grade 3 or 4 adverse events were reported in 14.4% of the patients in the nivolumab group and in 45.9% of those in the ipilimumab group; treatment was discontinued because of any adverse event in 9.7% and 42.6% of the patients, respectively. Two deaths (0.4%) related to toxic effects were reported in the ipilimumab group more than 100 days after treatment. CONCLUSIONS: Among patients undergoing resection of stage IIIB, IIIC, or IV melanoma, adjuvant therapy with nivolumab resulted in significantly longer recurrence-free survival and a lower rate of grade 3 or 4 adverse events than adjuvant therapy with ipilimumab. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 238 ClinicalTrials.gov number, NCT02388906 ; Eudra-CT number, 2014-002351-26 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nonetheless, adjuvant ICT has been successful in high-risk melanoma, which led to FDA approval (189-193).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [191]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationFinal Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationWeber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Self-citationCompletion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., Jahkola, T., Bowles, T. L., Testori, A., Beitsch, P. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613210 · Cited by 1,414
Research works printed but not linked: 1
- Tarhini AA, 2017, J Clin Oncol, 35
Cited by
Items 801–900 of 1,000
Dubois, M., Ardin, C., André, F., Scherpereel, A., & Mortier, L. (2019) · médecine/sciences · doi:10.1051/medsci/2019225 · Cited by 29
Self-citationBaetz, T. D., Fletcher, G. G., Knight, G. J., McWhirter, E., Rajagopal, S., Song, X., & Petrella, T. M. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102032 · Cited by 19
Fujikawa, I., Ando, T., Suzuki‐Karasaki, M., Suzuki‐Karasaki, M., Ochiai, T., & Suzuki‐Karasaki, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134771 · Cited by 18
“Specifically, the adjuvant use of nivolumab resulted in significantly extended recurrence-free survival [3].”
BackgroundGambichler, T., Tsagoudis, K., Kiecker, F., Reinhold, U., Stockfleth, E., Hamscho, R., Egberts, F., Hauschild, A., Amaral, T. M. S., & Garbe, C. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.10.016 · Cited by 18
Barreiro, A., Lencina, J. J. A., Podlipnik, S., Carrera, C., Requena, C., Manrique-Silva, E., Quaglino, P., Tonella, L., Jaka, A., Richarz, N. A., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2020.11.036 · Cited by 18
Dong, X., Song, J., Chen, B., Qi, Y., Jiang, W., Li, H., Zheng, D., Wang, Y., Zhang, X., & Liu, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.592811 · Cited by 19
Mitra, D., Ologun, G. O., Keung, E. Z.-Y., Goepfert, R. P., Amaria, R. N., Ross, M. I., Gershenwald, J. E., Lucci, A., Fisher, S. B., Davies, M. A., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-09804-3 · Cited by 18
How we treat locoregional melanoma
Troiani, T., Falco, V. D., Napolitano, S., Trojaniello, C., & Ascierto, P. A. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100136 · Cited by 25
Self-citationLiu, W., Liu, Y., Hu, C., Xu, C., Chen, J., Chen, Y., Cai, J., Yan, G., & Zhu, W. (2021) · International Journal of Cancer · doi:10.1002/ijc.33703 · Cited by 19
The sentinel node invasion level (SNIL) as a prognostic parameter in melanoma
Kretschmer, L., Mitteldorf, C., Hellriegel, S., Leha, A., Fichtner, A., Ströbel, P., Schön, M. P., & Bremmer, F. (2021) · Modern Pathology · doi:10.1038/s41379-021-00835-5 · Cited by 18
Advances in the discovery and development of melanoma drug therapies
Chanda, M., & Cohen, M. S. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1942834 · Cited by 26
Neoantigen-Reactive T Cells: The Driving Force behind Successful Melanoma Immunotherapy
Davis, L., Tarduno, A., & Lu, Y. (2021) · Cancers · doi:10.3390/cancers13236061 · Cited by 19
Schwarze, J. K., Garaud, S., Jansen, Y. J. L., Awada, G., Vandersleyen, V., Tijtgat, J., de Wind, A., Kristanto, P., Seremet, T., Willard-Gallo, K. E., et al. (2022) · Cancers · doi:10.3390/cancers14030682 · Cited by 20
“Moreover, irAE were significantly lower with either anti-PD-1 mAb [3].”
BackgroundBroman, K. K., Hughes, T. M., Bredbeck, B. C., Sun, J., Kirichenko, D., Carr, M. J., Sharma, A., Bartlett, E. K., Nijhuis, A. A. G., Thompson, J. F., et al. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000005370 · Cited by 19
Kudchadkar, R. R., Michielin, O. A., & van Akkooi, A. C. J. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200241 · Cited by 18
Self-citationHyperprogression with immunotherapy: Is it real?
Popat, S. (2019) · Cancer · doi:10.1002/cncr.31997 · Cited by 20
Cancer immunotherapy does not increase the risk of death by COVID-19 in melanoma patientsPreprint
González‐Cao, M., Antonazas-Basa, M., Puértolas, T., Muñoz‐Couselo, E., Manzano, J. L., Carrera, C., Márquez‐Rodas, I., Criado, P. L., Rodríguez-Moreno, J. F., García‐Castaño, A., et al. (2020) · medRxiv · doi:10.1101/2020.05.19.20106971 · Cited by 18
Current Trends of Immunotherapy in the Treatment of Cutaneous Melanoma: A Review
Naik, P. P. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00583-z · Cited by 18
“Ipilimumab is the most critical drug that inhibits CTLA-4 [47]; studies have indicated that this molecule has promising results and that the response is long-lasting, even after the treatment is stopped [63].”
BackgroundMethodInfluentialSentinel lymph nodes in melanoma: necessary as ever for optimal treatment
Faries, M. B. (2024) · Clinical & Experimental Metastasis · doi:10.1007/s10585-023-10254-2 · Cited by 18
“More recently, both targeted and immune checkpoint therapies have been developed and approved, making adjuvant therapy more broadly appealing [16, 17].”
BackgroundRessler, J. M., Tomasich, E., Hatziioannou, T., Ringl, H., Heller, G., Silmbrod, R., Gottmann, L., Starzer, A. M., Zila, N., Tschandl, P., et al. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01041-4 · Cited by 18
“…and could not predict a positive clinical outcome [3, 28], Robert et al. 2015; [46], which led to the approval of PD-1 inhibitors for melanoma in metastatic [23, 45] and adjuvant [43] settings by the US Food and Drug Administration irrespective of the PD-L1 expression status of the tumor tissue.”
Mukherjee, N., Katsnelson, E. N., Brunetti, T. M., Michel, K., Couts, K. L., Lambert, K. A., Robinson, W. A., McCarter, M. D., Norris, D. A., Tobin, R. P., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06524-w · Cited by 20
“Furthermore, liver toxicity is one of side effects reported by a fraction of patients treated with ICIs, such as Anti-PD-1 drug Pembrolizumab alone [59 – 61] or the combination of Anti-CTLA-4 with Anti-PD-1/PD-L1 [62].”
Garutti, M., Bruno, R., Polesel, J., Pizzichetta, M. A., & Puglisi, F. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32433 · Cited by 19
“Moreover, recent advancements in immunotherapy have highlighted the importance of the immune system in controlling cancer, leading to the investigation of both the prognostic and therapeutic utility of TILs in melanoma [21 – 25].”
BackgroundGuo, C., Dai, X., Du, Y., Xiong, X., & Gui, X. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03794-3 · Cited by 18
“In head-to-head comparison between anti-CTLA-4 and anti-PD-1 therapies, the former yields lower response rates and a higher incidence of immu-notherapy-related adverse effects (irAEs) than the latter [3–5].”
BackgroundJurlander, R. S., Guldbrandt, L. M., Holmstroem, R. B., Madsen, K. S., Donia, M., Haslund, C. A., Schmidt, H., Bastholt, L., Ruhlmann, C. H. B., Svane, I. M., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115053 · Cited by 20
Breslow Density Is a Novel Prognostic Feature That Adds Value to Melanoma Staging
Saldanha, G. S., Yarrow, J., Pancholi, J., Flatman, K., Teo, K. W., Elsheik, S., Harrison, R. F., O'Riordan, M., & Bamford, M. W. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001034 · Cited by 20
Li, J., & Gu, J. H. (2018) · Immunotherapy · doi:10.2217/imt-2018-0116 · Cited by 18
Li, J., & Gu, J. H. (2019) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12802 · Cited by 18
Guillot, B., Dupuy, A., Pracht, M., Jeudy, G., Hindié, E., Desmedt, E., Jouary, T., & Leccia, M. ‐. (2019) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2019.01.011 · Cited by 25
Najjar, Y. G., Puligandla, M., Lee, S. J., & Kirkwood, J. M. (2019) · Cancer · doi:10.1002/cncr.32162 · Cited by 17
“Missing data 1 (0) 0 (0) 1 (0) 0 (0) 2 (0) Site of primary tumor Head/neck 29 (10) 77 (12) 113 (13) 13 (12) 232 (12) Upper limb 41 (14) 97 (15) 113 (13) 14 (13) 265 (14) Lower limb 56 (20) 149 (23) 175 (20) 16 (15) 396 (21) Other 26 (9) 18 (3) 29 (3) 7 (7) 80 (4) Trunk 129 (45) 298 (46) 365 (42) 36 (34) 828 (43) Missi…”
Terheyden, P. A. M., Krackhardt, A. M., & Eigentler, T. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0497 · Cited by 32
“In the CA209–238 trial, nivolumab 3 mg/kg was evaluated versus ipilimumab 10 mg/kg. Recurrence-free Some studies reported unusual confidence intervals (for example, 97.5%; 98.4%), which can be explained by their methodological approach.. BID, twice daily; HR, hazard ratio; CI, confidence interval; NED, no evidence of…”
BackgroundInfluentialThe Role and Necessity of Sentinel Lymph Node Biopsy for Invasive Melanoma
Nakamura, Y. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00231 · Cited by 18
“A phase III randomized controlled trial (Checkmate 238) comparing nivolumab with ipilimumab for stage IIIB to IV melanoma patients (22) demonstrated better 1 year RFS with lower toxicity in the nivolumab group than in the ipilimumab group.”
Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma
Hemstock, M., Amadi, A., Kupas, K., Roskell, N., Kotapati, S., Gooden, K., Middleton, M. R., & Schadendorf, D. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.03.011 · Cited by 18
“Based on promising phase III trial results [17,18], nivolumab is now indicated for the adjuvant treatment of adults with melanoma with lymph node involvement or metastatic disease who have undergone complete resection [19,20].”
BackgroundMethodResultSelf-citationLiu, C., Zhang, Z., Yü, P., Qin, G., Zhang, K., Maimela, N. R., Huang, L. J., Yang, S., & Zhang, Y. (2020) · Cancer Management and Research · doi:10.2147/cmar.s238174 · Cited by 20
Luo, H., Zhang, T., Cheng, P., Li, D., Ogorodniitchouk, O., Lahmamssi, C., Wang, G., & Lan, M. (2020) · Oncology Letters · doi:10.3892/ol.2020.11858 · Cited by 19
“This leads to a dramatic change in treatment focus, from a metastatic to an adjuvant setting (78,79).”
BackgroundMiyashita, H., Mikami, T., Satoi, S., Cruz, C., & Galsky, M. D. (2020) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000339 · Cited by 17
In-transit metastatic cutaneous melanoma: current management and future directions
Patel, A. S., Carr, M. J., Sun, J. X., & Zager, J. S. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10100-3 · Cited by 17
Jia, D., Niu, Y.-L., Zhu, H., Wang, S., Ma, T., & Li, T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.675873 · Cited by 19
Li, J., Wang, J., Li, D., Wen, X., Ding, Y., Liu, X., Jiang, H., Huang, F., & Zhang, X. (2021) · Dermatologic Therapy · doi:10.1111/dth.15067 · Cited by 19
“Furthermore, no one discontinued adjuvant PD-1 inhibitor due to treatmentrelated toxicity, and no treatment-related deaths occurred.(6,7) And the adverse events recorded in the anti-PD-1 group was almost early toxicity that occurred during administration and within 6 months after drug withdrawal.”
BackgroundMandalà, M., Larkin, J., Ascierto, P. A., Vecchio, M. D., Gogas, H. J., Cowey, C. L., Arance, A. M., Dalle, S., Schenker, M., Grob, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003188 · Cited by 18
Self-citationMulder, E. E. A. P., Smit, L., Grünhagen, D. J., Verhoef, C. K., Sleijfer, S., van der Veldt, A. A. M., & Groot, C. A. U.-D. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100303 · Cited by 18
“Third, according to CEA guidelines, AEs were not included as no grade 3-4 AEs exceeded the threshold of 5% incidence.(16-18) Whereas the impact of AEs on ICERs is considered to be limited, patients suffer from these AEs, which can be lifelong and sometimes require lifelong therapy such as hormone replacement.”
BackgroundMethodAmabile, S., Roccuzzo, G., Pala, V., Tonella, L., Rubatto, M., Merli, M., Fava, P., Ribero, S., Fierro, M. T., Queirolo, P., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235475 · Cited by 17
“Higher DMFS was observed in the nivolumab group at a follow-up of 24, 36 and 48 months [31], while the median DMFS was not reached in either treatment group.”
Self-citationCai, Y., Liang, X., Zhan, Z., Zeng, Y., Lin, J., Xu, A., Xue, S., Xu, W., Chai, P., Mao, Y., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.812422 · Cited by 17
“PD-L1 expression within the tumor microenvironment has predictive value for assessing response to anti-PD-1/PD-L1 in many studies in melanoma (Weber et al., 2017), non-small-cell lung cancer (Fehrenbacher et al.”
BackgroundImpact of chronic lymphocytic leukaemia on melanoma outcomes: A retrospective case‐control study
Jobson, D., McCormack, C. J., Mar, V., Tam, C. S. L., & Henderson, M. A. (2022) · British Journal of Haematology · doi:10.1111/bjh.18090 · Cited by 18
Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma
Gartrell, R. D., Enzler, T., Kim, P., Fullerton, B. T., Fazlollahi, L., Chen, A., Minns, H. E., Perni, S., Weisberg, S. P., Rizk, E. M., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2066767 · Cited by 23
Lodde, G. C., Zimmer, L., Livingstone, E., Schadendorf, D., & Ugurel, S. (2020) · Der Pathologe · doi:10.1007/s00292-020-00776-x · Cited by 19
Moncrieff, M. D., Lo, S., Scolyer, R. A., Heaton, M. J., Nobes, J. P., Snelling, A. P., Carr, M. J., Nessim, C., Wade, R. G., Peach, A. H. S., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-11761-4 · Cited by 17
“Recently, several, prospective, randomized, controlled trials have shown clinical benefit of adjuvant systemic therapy, in terms of recurrence-free survival, for patients with metastatic melanoma.(7,25,26) As a result, most modern clinical guidelines recommend it for high-risk resected metastatic melanoma.”
BackgroundChye, A., Allen, I., Barnet, M. B., & Burnett, D. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.894015 · Cited by 17
The Role of Completion Lymph Node Dissection for Sentinel Lymph Node-Positive Melanoma
Hieken, T. J., Kane, J. M., & Wong, S. L. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6812-z · Cited by 17
Dillman, R. O., Cornforth, A. N., McClay, E. F., & DePriest, C. B. (2019) · Melanoma Management · doi:10.2217/mmt-2018-0010 · Cited by 19
Reprogramming lymphocytes for the treatment of melanoma: From biology to therapy
Margolis, N., Markovits, E., & Markel, G. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.06.005 · Cited by 20
Petrella, T. M., Fletcher, G. G., Knight, G. J., McWhirter, E., Rajagopal, S., Song, X., & Baetz, T. D. (2020) · Current Oncology · doi:10.3747/co.27.5933 · Cited by 17
Guía de práctica clínica de melanoma de la Academia Española de Dermatología y Venereología
Estrada, R. B., Boada, A., Carrera, C., Fernández‐Figueras, M. T., González‐Cao, M., Moreno-Ramírez, D., Nagore, E., Ríos‐Buceta, L., Rodríguez‐Peralto, J. L., Samaniego-González, E., et al. (2020) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2020.07.003 · Cited by 20
Patients with Metastatic Melanoma Receiving Anticancer Drugs: Changes in Overall Survival, 2010–2017
Poizeau, F., Kerbrat, S., Happe, A., Rault, C., Drézen, E., Balusson, F., Tuppin, P., Guillot, B., Thuret, A., Boussemart, L., et al. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.07.038 · Cited by 19
“Only patients treated with first-line ipilimumab in our study exhibited better survival than those reported in RCTs (Ugurel et al., 2017).”
BackgroundInfluentialAdjuvant Melanoma Therapy — Head-Spinning Progress
Schuchter, L. M. (2017) · New England Journal of Medicine · doi:10.1056/nejme1711199 · Cited by 19
Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?
Rothermel, L. D., & Zager, J. S. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1544614 · Cited by 17
Current management of patients with melanoma who are found to be sentinel node‐positive
Nijhuis, A. A. G., Spillane, A. J., Stretch, J. R., Saw, R. P. M., Menzies, A. M., Uren, R. F., Thompson, J. F., & Nieweg, O. E. (2019) · ANZ Journal of Surgery · doi:10.1111/ans.15491 · Cited by 16
“Results of the CheckMate 238 trial showed that recurrence-free survival with adjuvant nivolumab for 1 year was better than with ipilimumab in patients with stage IIIB, IIIC and stage IV disease, with less toxicity.(9) Local and distant recurrences were reduced on all trials to similar effect.”
MethodMallardo, D., Giannarelli, D., Vitale, M. G., Galati, D., Trillò, G., Esposito, A., Isgrò, M. A., D’Angelo, G., Festino, L., Vanella, V., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005132 · Cited by 21
Self-citationAri, S. L., Serzan, M. T., Wu, T., Ip, A., Pascual, L., Sinclaire, B., Adams, S., Marafelias, M., Ayyagari, L., Gill, S. K., et al. (2023) · Cancer · doi:10.1002/cncr.34742 · Cited by 17
“Musculoskeletal system 4 (1) 3 (3) 0 1 (1)”
Self-citationCombinational photodynamic and photothermal - based therapies for melanoma in mouse models
Lara-Vega, I., & Vega‐López, A. (2023) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2023.103596 · Cited by 16
Cass, S. H., Tobin, J. W. D., Seo, Y. D., Gener‐Ricos, G., Keung, E. Z.-Y., Burton, E. M., Davies, M. A., McQuade, J. L., Lazar, A. J., Mason, R., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.06.007 · Cited by 16
Self-citationSun, W., Xu, Y., Yan, W., Wang, C., Hu, T., Luo, Z., Zhang, X., Liu, X. Z., & Chen, Y. (2023) · Cancer Medicine · doi:10.1002/cam4.6234 · Cited by 16
van Akkooi, A. C. J., Mandalà, M., Nathan, P., Haydon, A. M., Postow, M. A., & Rutkowski, P. L. (2024) · EJC Skin Cancer · doi:10.1016/j.ejcskn.2024.100021 · Cited by 17
Self-citationUpdate on adjuvant melanoma therapy
Dimitriou, F., Braun, R. P., & Mangana, J. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000432 · Cited by 16
Uhara, H. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1246-y · Cited by 21
“Most recently, an adjuvant setting study comparing ipilimumab 10 mg/kg to nivolumab 3 mg/kg in stage IIIB, IIIC, or IV melanoma was reported [39].”
BackgroundMignard, X., Antoine, M., Moro‐Sibilot, D., Dayen, C., Mennecier, B., Gervais, R., Amour, E., Milleron, B. J., Morin, F., Zalcman, G., et al. (2018) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2018.08.006 · Cited by 18
Current management of regional lymph nodes in patients with melanoma
Bartlett, E. K. (2018) · Journal of Surgical Oncology · doi:10.1002/jso.25316 · Cited by 16
“The recently demonstrated efficacy of both targeted and immune therapies in the adjuvant setting makes accurate prognostic information critical to correctly selecting patients for therapy.(4-6) In the future, selecting patients for nodal intervention will likely be closely intertwined with the discussion to utilize ad…”
BackgroundSurgical Considerations and Systemic Therapy of Melanoma
Gamboa, A. C., Lowe, M., Yushak, M. L., & Delman, K. A. (2019) · Surgical Clinics of North America · doi:10.1016/j.suc.2019.09.012 · Cited by 17
Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy
Zubiri, L., Allen, I. M., Taylor, M. S., Guidon, A. C., Chen, S. T., Schoenfeld, S. R., Neilan, T. G., Sise, M. E., Mooradian, M. J., Rubin, K. M., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0883 · Cited by 16
“, for nivolumab in patients with melanoma [23] and durvalumab in patients with unresectable stage III NSCLC following chemoradiotherapy [45]).”
BackgroundPreferences of Canadian Patients and Physicians for Adjuvant Treatments for Melanoma
Stellato, D., Thabane, M. E., Eichten, C., & Delea, T. E. (2019) · Current Oncology · doi:10.3747/co.26.5085 · Cited by 17
Preclinical and clinical combination therapies in the treatment of anaplastic thyroid cancer
Gentile, D., Orlandi, P., Banchi, M., & Bocci, G. (2020) · Medical Oncology · doi:10.1007/s12032-020-1345-2 · Cited by 16
Nivolumab‐associated myositis myocarditis and myasthenia and anti‐striated muscle antibodies
Fazal, M., Prentice, D. A., Kho, L. K., & Fysh, E. T. H. (2020) · Internal Medicine Journal · doi:10.1111/imj.14946 · Cited by 16
Adjuvant therapy of operable nonsmall cell lung cancer: an update
Mitsudomi, T., & Soh, J. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000702 · Cited by 17
“Table 3 [26] summarizes the detection rate of patients with ctDNA detected using different platforms, showing that the detection rate is dependent on the tumor-node-metastasis stage [27 && ].”
BackgroundMethodInfluentialFarrow, N. E., Holl, E. K., Jung, J., Gao, J., Jung, S., Al-Rohil, R. N., Selim, M. A., Mosca, P. J., Ollila, D. W., Antonia, S. J., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09277-w · Cited by 16
High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy
Quek, C. Y. J., Bai, X., Long, G. V., Scolyer, R. A., & Wilmott, J. S. (2021) · Genes · doi:10.3390/genes12101629 · Cited by 16
Self-citationZhu, Z., Zhuang, L., Zhang, C., Ning, Z., Wang, D., Sheng, J., Hua, Y.-Q., Xie, J., Xu, L., & Meng, Z. (2021) · Translational Cancer Research · doi:10.21037/tcr-21-1760 · Cited by 16
Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy
Ng, G. K. H., Xu, W., & Atkinson, V. G. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01288-y · Cited by 17
“With an understanding of the mechanism of these agents and clinical outcomes in the metastatic setting, it is not surprising to find that the majority of relapses on adjuvant immunotherapy occur within the first 12 months while on treatment [6, 7, 13], but relapse during the first 12 months on adjuvant targeted therap…”
BackgroundSelf-citationExpert recommendations on diagnostic-therapeutic management of melanoma patients
Rutkowski, P. L., Wysocki, P. J., Kozak, K., Nasierowska-Guttmejer, A. M., Jeziorski, A., Wysocki, W. M., Kalinka‐Warzocha, E., Świtaj, T., Kamińska‐Winciorek, G., Czarnecka, A. M., et al. (2022) · Oncology in Clinical Practice · doi:10.5603/ocp.2021.0042 · Cited by 22
Self-citationPampena, M. B., Cartar, H. C., Cueto, G. R., Levy, E. M., Blanco, P. A., Barrio, M. M., & Mordoh, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02531 · Cited by 16
“With respect to adjuvant therapies in stage III patients, it has been reported that mutated BRAF inhibitors and anti-PD1 MAbs increase relapse-free survival, although follow-up is short and about two thirds of patients at risk of recurrence are unprotected (4, 5).”
BackgroundImmune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions
NIKE Group, Gallo, M., Guarnotta, V., de Cicco, F., Rubino, M., Faggiano, A., & Colao, A. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02839-w · Cited by 16
Lapman, S., Whittier, W. L., Parikh, R., Khanin, Y., Bijol, V., Wanchoo, R., & Jhaveri, K. D. (2020) · Journal of Onco-Nephrology · doi:10.1177/2399369320907598 · Cited by 16
“4(1-2) 52 –58 © The Author(s) 2020 Article reuse guidelines: sagepub.”
Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma
Jang, S., Poretta, T., Bhagnani, T., Harshaw, Q., Burke, M. M., & Rao, S. A. (2020) · Dermatology and Therapy · doi:10.1007/s13555-020-00404-9 · Cited by 16
Mowery, Y. M., Patel, K. R., Chowdhary, M., Rushing, C. N., Choudhury, K. R., Lowe, J. R., Olson, A. C., Wisdom, A. J., Salama, J. K., Hanks, B. A., et al. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2019.06.013 · Cited by 17
“Anti-PD-1 based therapies are a standard of care option for patients with unresectable melanoma and have demonstrated benefit in the adjuvant setting [1,2].”
BackgroundNelson, A., Krabbe, E., Björkström, K., Huibers, A. E., Jovanovic, B., Blank, C. U., Ullenhag, G. J., Helgadóttir, H., Ny, L., & Bagge, R. O. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115485 · Cited by 18
Role of immunotherapy in stage IIIA non-small cell lung cancer: a narrative review
Calvo, V., Sierra‐Rodero, B., Cruz‐Bermúdez, A., & Provencio, M. (2021) · Current Challenges in Thoracic Surgery · doi:10.21037/ccts-20-82 · Cited by 15
“(36), followed by nivolumab (37) and pembrolizumab (anti-PD-1) (38).”
BackgroundSentinel lymph node biopsy is associated with increased cost in higher risk thin melanoma
Aiken, T. J., Stahl, C. C., Schwartz, P. B., Barrett, J. R., Acher, A. W., Lemaster, D. M., LEVERSON, G. E., Weber, S. M., Neuman, H. B., & Abbott, D. E. (2020) · Journal of Surgical Oncology · doi:10.1002/jso.26225 · Cited by 15
Reschke, R., Gussek, P., & Ziemer, M. (2021) · Cancers · doi:10.3390/cancers13122902 · Cited by 15
Dougan, M. L. (2023) · Immunological Reviews · doi:10.1111/imr.13239 · Cited by 17
Rogiers, A., Willemot, L., McDonald, L., Campenhout, H. V., Berchem, G., Jacobs, C., Blockx, N., Rorive, A., & Neyns, B. (2023) · Cancers · doi:10.3390/cancers15194823 · Cited by 15
“Based on the primary analysis of CheckMate 238 [1], nivolumab was approved in 2018 by the European Medicines Agency as an adjuvant treatment for patients with resected melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection [5], and it became the first…”
BackgroundMethodResultInfluentialFilho, R. S. D. O., de Oliveira, D. A., Nisimoto, M. Y. S. M., & Marti, L. C. (2023) · Cancers · doi:10.3390/cancers15245751 · Cited by 18
Muto, Y., Fujimura, T., & Asano, Y. (2025) · Cancers · doi:10.3390/cancers17132265 · Cited by 17
“C or stage IV melanoma [41,42].”
Ziogas, D. E., Kyrochristos, I. D., & Roukos, D. H. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.07.008 · Cited by 17
Hawkins, M. L., Rioth, M. J., Eguchi, M., & Cockburn, M. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.01.009 · Cited by 15
Ipenburg, N. A., Thompson, J. F., Uren, R. F., Chung, D. K. V., & Nieweg, O. E. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07505-6 · Cited by 16
Ascierto, P. A., Agarwala, S. S., Botti, G., Budillon, A., Davies, M. A., Dummer, R., Ernstoff, M. S., Ferrone, S., Formenti, S. C., Gajewski, T. F., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1979-z · Cited by 16
Self-citationSong, Y., Straker, R. J., Xu, X., Elder, D. E., Gimotty, P. A., Huang, A. C. C., Mitchell, T. C., Amaravadi, R. K., Schuchter, L. M., & Karakousis, G. C. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-019-08174-1 · Cited by 16
“Although a statistically significant difference in overall pathologic response was not observed by the specific ICB agent utilized in the current study, clinical trials have shown that anti-PD-1 therapies are associated with higher response rates and survival outcomes than ipilimumab alone.(5,19,20) For example, recen…”
ResultZhao, B., Zhao, H., & Zhao, J. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919895753 · Cited by 20
Hanks, J. E., Kovatch, K. J., Ali, S. A., Roberts, E., Durham, A. B., Smith, J. D., Bradford, C. R., Malloy, K. M., Boonstra, P. S., Lao, C. D., et al. (2020) · Otolaryngology · doi:10.1177/0194599819899934 · Cited by 16
Adjuvant Therapy Failure Patterns in the Modern Era of Melanoma Management
Rauwerdink, D. J. W., Molina, G., Frederick, D. T., Sharova, T., Carmichael, H., & Boland, G. M. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08631-2 · Cited by 16
Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens
Yao, J., Li, M., Zhang, H., Ge, Y., Weygant, N., & An, G. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106770 · Cited by 15
Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1
Fan, J., Shen, X., Wang, Y., Zhou, H., Liu, G., Li, Y., & Xu, Z. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110621 · Cited by 15
Metadata
- Authors
- Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., Grob, J.-J., Butler, M. O., Middleton, M. R., Maio, M., Atkinson, V., Queirolo, P., Gonzalez, R., Kudchadkar, R. R., Smylie, M., Meyer, N., Mortier, L., Atkins, M. B., Long, G. V., Bhatia, S., Lebbé, C., Rutkowski, P., Yokota, K., Yamazaki, N., Kim, T. M., de Pril, V., Sabater, J., Qureshi, A., Larkin, J., & Ascierto, P. A.
- Affiliations
- University of Siena (IT)
- ORCID
- Weber, Jeffrey
- Gogas, Helen J.
- Arance, Ana M.
- Cowey, C. Lance
- Dalle, Stéphane
- Schenker, Michael
- Grob, Jean-Jacques
- Butler, Marcus O.
- Middleton, Mark R.
- Maio, Michele
- Atkinson, Victoria
- Queirolo, Paola
- Gonzalez, Rene
- Kudchadkar, Ragini R.
- Smylie, Michael
- Mortier, Laurent
- Atkins, Michael B.
- Long, Georgina V.
- Bhatia, Shailender
- Rutkowski, Piotr
- Yokota, Kenji
- Yamazaki, Naoya
- Sabater, Javier
- Larkin, James
- Ascierto, Paolo A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-09
- Volume
- 377
- Issue
- 19
- Pages
- 1824-1835
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2752227448
- Cited by
- 2,246
- References
- 19
- Citations by year
- 2026: 105 · 2025: 155 · 2024: 218 · 2023: 228 · 2022: 265 · 2021: 339 · 2020: 347 · 2019: 315 · 2018: 245 · 2017: 24
- FWCI
- 112.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
- Research Explorer (The University of Manchester) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Cancer Research UK (18892, 15951, 20613, 22795)
- Medical Research Council (MR/P024351/1)
- Japan Society for the Promotion of Science (16K10165)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- nivolumab, ipilimumab, adjuvant therapy, advanced melanoma, immune checkpoint inhibitors, recurrence-free survival, PD-1 inhibitors, CTLA-4 inhibitors, R0 resection, treatment-related adverse events, melanoma recurrence, overall survival, progression-free survival
- MeSH terms
- Ipilimumab, Nivolumab, Cutaneous Malignant Melanoma, Adjuvants, Immunologic, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Quality of Life, Skin Neoplasms, Disease-Free Survival, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.